verified SJR 5,514 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Harborside Press

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription

Journal of the National Comprehensive Cancer Network : JNCCN

Journal of the National Comprehensive Cancer Network : JNCCN is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 162. It has an SJR impact factor of 5,514 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 5,514.

ISSN: 1540-1405

Publisher: Harborside Press

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

5,514 Q1

H-index 162

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

5,514

H-index

162

Docs (year)

159

Docs 3y

609

Total refs

7107

Cites 3y

6923

Citable 3y

514

Cites/Doc 2y

11.49

Ref/Doc

44.7

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

BPI20-021: Metastatic Renal Cell Carcinoma and Immunotherapy, Experience in a Third Level Hospital in Mexico City

YIA20-005: Rapid Point of Care assay by isothermal PCR for Acute Promyelocytic Leukemia Diagnosis

CLO20-033: A Study of Pathological Characteristics of Malignant Cribriform Prostatic Lesions

CLO20-031: Radiotherapy-Induced Malignancies in Breast Cancer Patients With Pathogenic Germline Variants TP53 in an R337H-Mutation Enriched Cohort

CLO20-030: Sex-Based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma

CLO20-029: The Prognostic and Predictive Significance of Joint Investigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients

CLO20-028: Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients who have Failed Standard of Care Treatments

Carcinoma of Unknown Primary: Focused Evaluation

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

BPI20-025: Aligning Genetic Panel Utilization With Clinical Practice Guidelines Through Education

BPI20-023: International Adaptation of the Resource-Stratified NCCN Frameworks for Breast, Cervical and Rectal Cancers in Bolivia

SHOW MORE ARTICLES

BPI20-022: Use of Cyclin Dependent Kinase 4/6 Inhibitors in Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer. Experience in a Third Level Hospital in Mexico City

Adolescent and Young Adult Oncology, Version 2.2014

BPI20-020: Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making

BPI20-018: Direction of Developing Cancer Survivorship Guidelines in Japan: An Expert Panel's Consensus

BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time

BPI20-016: Comparative Study Between the Clinical Effect of Palonosetron and Granisetron as Antiemetic Therapy for Patients Receiving Highly Emetogenic Chemotherapy Regimens

BPI20-015: Safety and Financial Analysis of Outpatient Dose-Adjusted EPOCH for B-cell Lymphoma at a Tertiary Comprehensive Cancer Center

BPI20-013: A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma

BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis

BPI20-011: Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens

BPI20-009: Impact of Preoperative Biliary Drainage on Postoperative Outcome for Obstructive Jaundice Patients

BPI20-008: Pilot Testing of InheRET‚Ñ¢, an Online Tool to Facilitate NCCN Guideline¬Æ-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care

FAQs

Journal of the National Comprehensive Cancer Network : JNCCN has an SJR of 5,514 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Journal of the National Comprehensive Cancer Network : JNCCN is 23%.

Journal of the National Comprehensive Cancer Network : JNCCN

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Journal of the National Comprehensive Cancer Network : JNCCN?

What is the APC / publication cost?

What is the acceptance rate?